Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRE11 | P49959 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484736 | 0.87 | MRE11 (1.00) | MRE11 | |
| SCHEMBL21484710 | 0.87 | MRE11 (1.00) | MRE11 | |
| SCHEMBL21484697 | 0.85 | MRE11 (1.00) | MRE11 | |
| SCHEMBL21484659 | 0.84 | MRE11 (0.79) | MRE11 | |
| SCHEMBL21484635 | 0.82 | MRE11 (1.00) | MRE11 | |
| SCHEMBL21484755 | 0.80 | MRE11 (0.75) | MRE11 | |
| SCHEMBL21484666 | 0.80 | MRE11 (1.00) | MRE11 | |
| SCHEMBL21484700 | 0.80 | MRE11 (0.78) | MRE11 | |
| SCHEMBL21484677 | 0.80 | MRE11 (1.00) | MRE11 | |
| SCHEMBL21484664 | 0.79 | MRE11 (1.00) | MRE11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2022-09-27 | — | — | US | disclosed |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-03-10 | — | — | US | disclosed |
| EP-3556756-B1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2020-10-07 | — | — | EP | disclosed |
| EP-3556756-B1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2020-10-07 | — | — | EP | disclosed |
| WO-2019201867-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| EP-3556756-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556756-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | DNASE1, RNASEH1, FEN1 | MRE11 86/4885 |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | DNASE1, RNASEH1, FEN1 | MRE11 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.